Physician profile
Mary Windham
NPI 1417485830
$1,927.97
in general payments reported to CMS, 2019-2025
27 companies · $1,538 in 2025
The $1,538 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $390 · 2025: $1,538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,928.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,927.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $406.12 | 2024-2025 | Evenity, Tepezza, Prolia |
| Ascendis Pharma Endocrinology INC | $263.60 | 2024-2025 | Yorvipath |
| Lilly USA, LLC | $126.14 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Abbott Laboratories | $115.13 | 2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.91 | 2025 | Jardiance |
| Insulet Corporation | $97.33 | 2025 | Omnipod |
| Radius Health, INC. | $96.40 | 2024-2025 | Tymlos |
| Chiesi USA, INC. | $79.71 | 2025 | Mycapssa |
| Novo Nordisk INC | $76.49 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Mannkind Corporation | $75.11 | 2025 | |
| Tandem Diabetes Care, INC. | $52.16 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sequel Med Tech, LLC | $47.36 | 2025 | Twiist |
| Kyowa Kirin, INC. | $41.44 | 2024-2025 | Crysvita |
| Medtronic, INC. | $39.32 | 2025 | Minimed 780g |
| Alexion Pharmaceuticals, INC. | $34.28 | 2024 | Strensiq |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $34.03 | 2025 | Isturisa |
| Neurocrine Biosciences, INC. | $32.00 | 2025 | |
| Beta Bionics, INC. | $27.69 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Corcept Therapeutics | $23.91 | 2025 | Korlym |
| Sandoz INC. | $23.65 | 2025 | Jubbonti |
| Ibsa Pharma INC. | $23.59 | 2025 | Flector, Tirosint, Licart |
| Madrigal Pharmaceuticals | $21.32 | 2025 | Rezdiffra |
| Novartis Pharmaceuticals Corporation | $20.10 | 2025 | |
| Xeris Pharmaceuticals, INC. | $18.34 | 2025 | Recorlev |
| Acella Pharmaceuticals, LLC | $18.23 | 2025 | NP Thyroid 60 |
| Currax Pharmaceuticals LLC | $14.48 | 2024 | Contrave |
| Almatica Pharma LLC | $14.13 | 2025 | Teriparatide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Windham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.